Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

189.27USD
9:02pm BST
Change (% chg)

$2.12 (+1.13%)
Prev Close
$187.15
Open
$185.00
Day's High
$190.57
Day's Low
$182.88
Volume
1,131,966
Avg. Vol
525,014
52-wk High
$256.78
52-wk Low
$182.88

Select another date:
Photo

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

UPDATE 2-Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis.

UPDATE 1-Native American tribe holding patents sues Amazon and Microsoft

Oct 18 A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm.

ST REGIS MOHAWK TRIBE IS HOLDING PATENTS FOR SRC LABS IN DEAL SIMILAR TO ONE IT HAS WITH ALLERGAN

ST REGIS MOHAWK TRIBE IS HOLDING PATENTS FOR SRC LABS IN DEAL SIMILAR TO ONE IT HAS WITH ALLERGAN

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

BRIEF-Neos therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

RPT-ANALYSIS-Allergan ruling casts doubt on tribal patent strategy

Oct 17 A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion (1.14 billion pounds) dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

ANALYSIS-Allergan ruling casts doubt on tribal patent strategy

Oct 17 A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Select another date: